CSL (CSLLY) Stock Forecast & Price Target

CSL
Bull Case

Here are some ways that investors could benefit from investing in CSL Limited:

• CSL Limited has agreed to lower prices in a sweeping deal with the Trump administration, which expands the company's participation in Most Favored Nation agreements covering a significant portion of the branded drug market, potentially stabilizing its revenue streams in the US.
• The stock is currently trading at $31.61, which is significantly above its 52-week low of $16.01, indicating a strong recovery trend and suggesting that the market may be pricing in the worst of recent challenges as the company's latest results suggest the bottom may have been reached.
• Short interest in CSL Limited has declined by 32.7% in the most recent reporting period, dropping to 219,694 shares, which signals a reduction in bearish sentiment and a potential shift in market confidence toward the stock.
• CSL Limited reported positive top-line Phase 3b results for ANDEMBRY in children with hereditary angioedema, supporting a planned expanded pediatric filing that could broaden the product's market reach and future revenue potential.
• The company offers a dividend yield of 1.86%, providing a steady income stream for investors while the stock exhibits a low beta of 0.61, which suggests lower volatility compared to the broader market.